We are a contract research organization (CRO) that increase the speed for your pre-clinical drug development 

Subscribe to our newsletter

Drug Discovery Accelerated

Many drugs fail at late stages of development due to efficacy issues.

BioReperia has developed a unique zebrafish tumor xenograft (ZTX™) technology platform that provides functional in-vivo data to evaluate treatment efficacy for tumor regression and metastasis inhibition in only 5 days.

Our goal is to increase the speed and accuracy of preclinical drug development for cancer treatment, enabling you to select the lead candidates with the highest potential to succeed in less time.

See more

Our Unique Solution

Drug Discovery Solution

We provide a humanized, in-vivo oncology drug discovery platform, ZTX™ ONCOLEADS, that mimics the complex tumor environment, allowing you to select the best lead candidates for further pharmaceutical development within 5 days.

Learn more

Precision Medicine Solution

Our ZTX™ PREDICT platform identifies the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment.

Learn more
23 September 2022
Latest news
BioReperia will be hosting a webinar "how to evaluate drug candidates in a novel in vivo system - pros and cons" given by Dr. Anna Erkstam. In this webinar we will present the ZTX model and discuss the pros and cons and compared to other models commonly used in drug development today like mice, organoids […]
Read more
1 2 3 23
  • In our academic research, we look for small molecular compounds with antiepileptic properties.

    BioReperia supplied us with zebrafish larvae and they performed toxicology tests of our compounds prior to our electrophysiological recordings. The collaboration with BioReperia has worked very well, they are responsive to our needs and are willing to share their knowledge. Without their flexibility and knowledge, our recordings would have been very difficult to perform.

    Pre-clinical researcher, PhD
    Linköping University
  • BioReperia´s innovative technology speeds up the process to mammalian testing

    Bioreperia's innovative approach based on ZTX™ ONCOLEADS has been very useful for screening and accelerating our discovery program toward mammalian testing. From support of study design to full interpretation of results, our experience has been rewarding. Finally, the Swedish management style was quite agreeable on a more personal level.

    Researcher, CEO
    SME, Switzerland

We care about reducing cancer mortality for patients

BioReperia is a contract research laboratory (CRO) that is dedicated to providing a unique service to accelerate anti-cancer drug discovery. Our goal is to assist each customer to efficiently select the best new drug candidates and move them rapidly from preclinical to early stage clinical development. We can make something great together!

Learn more
Contact Form

Get in touch

Ask your questions or request an introductory call.